Recent Research Analysts’ Ratings Updates for Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (NASDAQ: INO) has recently received a number of price target changes and ratings updates:

  • 3/15/2018 – Inovio Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada from $11.00 to $14.00. They now have an “outperform” rating on the stock.
  • 3/15/2018 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/15/2018 – Inovio Pharmaceuticals was given a new $8.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 3/14/2018 – Inovio Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/7/2018 – Inovio Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 3/1/2018 – Inovio Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 2/15/2018 – Inovio Pharmaceuticals had its price target lowered by analysts at Maxim Group from $12.00 to $8.00. They now have a “buy” rating on the stock.
  • 2/13/2018 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 2/3/2018 – Inovio Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/24/2018 – Inovio Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/24/2018 – Inovio Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 1/23/2018 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Inovio Pharmaceuticals Inc (NASDAQ INO) opened at $4.84 on Friday. Inovio Pharmaceuticals Inc has a twelve month low of $3.76 and a twelve month high of $9.86. The company has a market capitalization of $404.11, a PE ratio of -4.48 and a beta of 2.55.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. Inovio Pharmaceuticals had a negative return on equity of 67.58% and a negative net margin of 208.92%. The company had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $9.13 million. During the same period last year, the business posted ($0.35) EPS. Inovio Pharmaceuticals’s revenue for the quarter was up 3.5% on a year-over-year basis. analysts forecast that Inovio Pharmaceuticals Inc will post -1.37 EPS for the current year.

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply